We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

Schedule an appointment today

CASE5221 Study

Pilot Study of NP-101 (TQ Formula) in Combination with Nivolumab and Ipilimumab in Advanced and/or Metastatic Extrapulmonary High-Grade Neuroendocrine Carcinomas (EP-NECAs)

Carcinoid Tumor of Colon


AGE: 18+ years old
CONDITION: High-Grade Neuroendocrine Carcinoma
TYPE: Interventional Study
LOCATION: UH Cleveland Medical Center

Learn More About This Research Study

To learn more about this study, please call study coordinator, Debbie Donohue at 216-844-4784 or complete the online form below.

Study Purpose

The purpose of this study is to find out if an investigational drug, NP-101 (TQ Formula) given with the immunotherapy drugs, nivolumab and Ipilimumab, helps patients with high-grade neuroendocrine carcinoma who have progressed on first line therapy.

Who Can Participate

Participants 18 years old and older diagnosed with high-grade neuroendocrine carcinoma and the disease is progressing after the first line of chemotherapy may be eligible for this study.

To learn more about this study, please fill out the form below to request more information.